Ocumension Therapeutics announced that an investigational new drug approval for initiating a multi-regional phase III clinical trial in the United States for OT-101, a self developed product of the Group, has been received from the United States Food and Drug Administration in February 2021. The company plans to file IND applications with the regulatory authorities in both China and Europe Union in 2021 and initiate the Phase III MRCT of OT-101 in these regions accordingly. OT-101 is a low-concentration atropine 0.01% eye drop developed by the Group to retard, or slow down, the progression of myopia in children and adolescents. The instability of low-concentration atropine solutions has long been a technical barrier for its commercialization. The Group developed a storage and delivery system to address low-concentration atropine solution's instability, and also conducted several rounds of tests on the system's reliability, closure integrity and sterility conditions.